Abstracts tagged "malignancy and vasculitis"

Abstract Number: 869 • 2015 ACR/ARHP Annual Meeting
Lymphoma in Patients with Granulomatosis with Polyangiitis
Karin Hjorton¹, Erik Hellbacher¹, Christer Sundstrom², Eva Baeckstrom¹ and Ann Knight¹, ¹Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, ²Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden
Background/Purpose: The risk of malignancy in patients with Granulomatosis with Polyangiitis (GPA) is increased, as shown in several previous studies. The risk of lymphoma has…
Abstract Number: 2639 • 2013 ACR/ARHP Annual Meeting
Long-Term Outcome of Monoclonal (type 1) Cryoglobulinemia
Antoine Néel¹, François Perrin¹, Olivier Decaux², Thomas Dejoie³, Maxime Halliez³, Béatrice Mahé⁴, Thierry Lamy⁵, Fadi Fakhouri⁶, Patrick Jego², Christian Agard¹, Cécile Vigneau⁷, Lucienne Guenet⁸, Bernard Grosbois⁹, Philippe Moreau⁴ and Mohamed Hamidou¹, ¹Internal Medicine Department, Nantes University Hospital, Nantes, France, ²Department of Internal Medicine, Rennes University Hospital, Rennes, France, ³Biochemistry Laboratory, Nantes University Hospital, Nantes, France, ⁴Hematology, Nantes University Hospital, Nantes, France, ⁵Hematology, Rennes University Hospital, Rennes, France, ⁶Nephrology, Nantes University Hospital, Nantes, France, ⁷Nephrology, Rennes University Hospital, Rennes, France, ⁸Biochemistry Laboratory, Rennes University Hospital, Rennes, France, ⁹Internal Medicine Department, Rennes University Hospital, Rennes, France
Background/Purpose: To investigate long-term outcome of symptomatic type 1 cryoglobulinemia and its determinants. Methods: Retrospective analysis of a prospective cohort from 2 French university hospitals.…
Abstract Number: 1548 • 2012 ACR/ARHP Annual Meeting
Cutaneous Vasculitis as a Paraneoplastic Syndrome
Javier Loricera¹, Vanesa Calvo-Rio², Francisco Ortiz Sanjuan³, Marcos Antonio Gonzalez-Lopez⁴, Hector Fernandez-Llaca⁴, Javier Rueda-Gotor², Carmen Gonzalez-Vela⁵, Cristina Mata-Arnaiz³, Miguel A. Gonzalez-Gay² and Ricardo Blanco², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁴Dermatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose: Cutaneous Leukocytoclastic Vasculitis (CLV) may be associated with malignancies, and sometimes it behaves as a paraneoplastic syndrome. This association has been reported in a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].